COVID-19 is an infectious disease caused by the SARS-CoV-2 virus, ranging from asymptomatic infection to severe respiratory and systemic illness.
FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine for adults 50+. It was 27% more effective than standard flu shots in a large trial. The approval came after earlier FDA pushback.
Moderna posted Q2 2026 revenue of $145 million and a GAAP net loss of $0.8 billion, while improving its 2026 spending outlook. Its norovirus candidate missed Phase 3 interim criteria, and mFLUSIVA faces an August 5 PDUFA decision.
FDA's advisory committee voted 9-0 that Moderna's mRNA flu vaccine mFlusiva benefits outweigh risks for adults 50-64 and 65+, clearing a key hurdle before an Aug. 5, 2026 decision. The FDA initially declined to review the BLA before reversing course.
A recent global analysis shows oncology dominates clinical trial activity in 2025, while Phase II attrition rates dropped to 26%—the lowest in four years. The US remains the leader in investigator sites, but China is the fastest-growing market. Obesity research is poised to break into the top five most-studied diseases.
CDC suppressed COVID-19 vaccine data; federal agencies may remove vaccines from the US market. Clinicians cite a JAMA study: 40% efficacy against hospitalization, 79% against severe outcomes.
The FDA reversed its initial rejection of Moderna's mRNA flu vaccine, agreeing to a normal review after public backlash, while a federal judge invalidated the ACIP advisory committee, leaving the US without functioning vaccine oversight. Moderna's vaccine showed 26.6% greater efficacy than standard flu shots in clinical trials.
Retail pharmacy chains that expanded into clinical trials after COVID have since slowed or pulled back. CVS said it would exit by the end of 2024, Walmart shut its health clinics in 2024, and Walgreens has not commented formally on its business status.
The UK has begun a 4,000-volunteer H5N1 bird flu vaccine trial using mRNA technology. The study will assess safety and immune response, with CEPI providing £40m in funding.
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07221097 |
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses |
RECRUITING | |
| NCT07196306 |
Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19 |
WITHDRAWN | PHASE2 |
| NCT06821139 |
Cohort Study of Intraoperative Lung Protective Ventilation Trends in a Large Canadian Health Authority |
COMPLETED | |
| NCT06763887 |
Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population |
COMPLETED | |
| NCT06744660 |
Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test |
RECRUITING | NA |
| NCT06692400 |
The Effects of Endotracheal Suctioning on Pain and Serum Markers |
RECRUITING | NA |
| NCT06652451 |
Covid-19 Data Analyses in Brazil |
COMPLETED | |
| NCT05137795 |
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 |
WITHDRAWN | PHASE3 |
| NCT04946162 |
The Use of Tadalafil in Confirmed COVID-19 Pneumonia. |
WITHDRAWN | PHASE4 |
| NCT04916561 |
Detection of Covid-19 in Tissue Samples of Orthopedic Origin |
COMPLETED |
